Thermo Fisher Scientific is providing proteomics and biopharmaceutical research laboratories with a new line of low-flow HPLC columns that improve separation performance and stability of biologically complex samples.

Waters Corp announces RapiZyme™ Trypsin, a chemically optimized, recombinant trypsin. This trypsin provides gold-standard performance while cutting lengthy digestion times from over three hours to just 30 minutes.

Owlstone Medical has announced the publication of a peer-reviewed study that identifies a set of volatile organic compounds that can identify patients with liver disease and separate them based on severity.

Ubiquigent Limited has announced it is supporting a Master’s student at the University of Glasgow to undertake a research project on USP30, a deubiquitinase implicated in neurodegenerative, renal and cardiovascular diseases.

GenNext Technologies, Inc. has selected Dr. Lisa Jones as the company’s new chief science officer.

Bruker Corporation and Switzerland-based Biognosys AG have announced a strategic partnership in which Bruker has made a majority-ownership investment in Biognosys.

Mainz Biomed NV has announced the first patient has been enrolled in eAArly DETECT, Mainz’s U.S. extension of ColoFuture, its European feasibility study evaluating the integration of a portfolio of novel gene expression (mRNA) biomarkers into ColoAlert.

Lipotype GmbH announces the launch of its first US subsidiary, Lipotype Inc.

Mainz Biomed has received approval from an independent Institutional Review Board for the protocol ReconAAsense, the Company’s US pivotal study to evaluate the clinical performance of its highly efficacious and easy-to-use detection test for colorectal cancer.

Open competition allows researchers to be among the first to access potentially groundbreaking proteomic data through the testing of twelve samples on Nautilus’ single-molecule protein analysis platform.